Global Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Research Report 2025

Publication ID:

PB501254356

Publication Date:

January 6, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for Human Cytomegalovirus Envelope Glycoprotein B was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Human Cytomegalovirus Envelope Glycoprotein B is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Human Cytomegalovirus Envelope Glycoprotein B is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Human Cytomegalovirus Envelope Glycoprotein B include Astellas Pharma Inc., Trellis Bioscience, Inc., Vakzine Projekt Management GmbH, VBI Vaccine Inc, Vical Incorporated, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Human Cytomegalovirus Envelope Glycoprotein B, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Cytomegalovirus Envelope Glycoprotein B.
The Human Cytomegalovirus Envelope Glycoprotein B market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Human Cytomegalovirus Envelope Glycoprotein B market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Cytomegalovirus Envelope Glycoprotein B manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Astellas Pharma Inc.
Trellis Bioscience, Inc.
Vakzine Projekt Management GmbH
VBI Vaccine Inc
Vical Incorporated
Segment by Type
CSJ-148
CyMVectin
TRL-345
PPCM
Cytomegalovirus Vaccine
Others
Segment by Application
Infectious Disease
Oncology
Women's Health
Others
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Human Cytomegalovirus Envelope Glycoprotein B manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Human Cytomegalovirus Envelope Glycoprotein B in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Overview
1.1 Product Definition
1.2 Human Cytomegalovirus Envelope Glycoprotein B by Type
1.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Value Comparison by Type (2024 VS 2031)
1.2.2 CSJ-148
1.2.3 CyMVectin
1.2.4 TRL-345
1.2.5 PPCM
1.2.6 Cytomegalovirus Vaccine
1.2.7 Others
1.3 Human Cytomegalovirus Envelope Glycoprotein B by Application
1.3.1 Global Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Value by Application (2024 VS 2031)
1.3.2 Infectious Disease
1.3.3 Oncology
1.3.4 Women's Health
1.3.5 Others
1.4 Global Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue 2020-2031
1.4.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales 2020-2031
1.4.3 Global Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Competition by Manufacturers
2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales 麻豆原创 Share by Manufacturers (2020-2025)
2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue 麻豆原创 Share by Manufacturers (2020-2025)
2.3 Global Human Cytomegalovirus Envelope Glycoprotein B Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Human Cytomegalovirus Envelope Glycoprotein B, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Human Cytomegalovirus Envelope Glycoprotein B, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Human Cytomegalovirus Envelope Glycoprotein B, Product Type & Application
2.7 Global Key Manufacturers of Human Cytomegalovirus Envelope Glycoprotein B, Date of Enter into This Industry
2.8 Global Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Competitive Situation and Trends
2.8.1 Global Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest Human Cytomegalovirus Envelope Glycoprotein B Players 麻豆原创 Share by Revenue
2.8.3 Global Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Scenario by Region
3.1 Global Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region: 2020-2031
3.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region: 2020-2025
3.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region: 2026-2031
3.3 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Region: 2020-2031
3.3.1 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Region: 2020-2025
3.3.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Region: 2026-2031
3.4 North America Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Facts & Figures by Country
3.4.1 North America Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2020-2031)
3.4.3 North America Human Cytomegalovirus Envelope Glycoprotein B Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Facts & Figures by Country
3.5.1 Europe Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2020-2031)
3.5.3 Europe Human Cytomegalovirus Envelope Glycoprotein B Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B Sales by Region (2020-2031)
3.6.3 Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2020-2031)
3.7.3 Latin America Human Cytomegalovirus Envelope Glycoprotein B Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2020-2031)
3.8.3 Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Type (2020-2031)
4.1.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Type (2020-2025)
4.1.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Type (2026-2031)
4.1.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales 麻豆原创 Share by Type (2020-2031)
4.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Type (2020-2031)
4.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Type (2020-2025)
4.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Type (2026-2031)
4.2.3 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue 麻豆原创 Share by Type (2020-2031)
4.3 Global Human Cytomegalovirus Envelope Glycoprotein B Price by Type (2020-2031)
5 Segment by Application
5.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Application (2020-2031)
5.1.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Application (2020-2025)
5.1.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Application (2026-2031)
5.1.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales 麻豆原创 Share by Application (2020-2031)
5.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Application (2020-2031)
5.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Application (2020-2025)
5.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Application (2026-2031)
5.2.3 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue 麻豆原创 Share by Application (2020-2031)
5.3 Global Human Cytomegalovirus Envelope Glycoprotein B Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Astellas Pharma Inc.
6.1.1 Astellas Pharma Inc. Company Information
6.1.2 Astellas Pharma Inc. Description and Business Overview
6.1.3 Astellas Pharma Inc. Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Astellas Pharma Inc. Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
6.1.5 Astellas Pharma Inc. Recent Developments/Updates
6.2 Trellis Bioscience, Inc.
6.2.1 Trellis Bioscience, Inc. Company Information
6.2.2 Trellis Bioscience, Inc. Description and Business Overview
6.2.3 Trellis Bioscience, Inc. Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Trellis Bioscience, Inc. Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
6.2.5 Trellis Bioscience, Inc. Recent Developments/Updates
6.3 Vakzine Projekt Management GmbH
6.3.1 Vakzine Projekt Management GmbH Company Information
6.3.2 Vakzine Projekt Management GmbH Description and Business Overview
6.3.3 Vakzine Projekt Management GmbH Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Vakzine Projekt Management GmbH Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
6.3.5 Vakzine Projekt Management GmbH Recent Developments/Updates
6.4 VBI Vaccine Inc
6.4.1 VBI Vaccine Inc Company Information
6.4.2 VBI Vaccine Inc Description and Business Overview
6.4.3 VBI Vaccine Inc Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2020-2025)
6.4.4 VBI Vaccine Inc Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
6.4.5 VBI Vaccine Inc Recent Developments/Updates
6.5 Vical Incorporated
6.5.1 Vical Incorporated Company Information
6.5.2 Vical Incorporated Description and Business Overview
6.5.3 Vical Incorporated Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Vical Incorporated Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
6.5.5 Vical Incorporated Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Cytomegalovirus Envelope Glycoprotein B Industry Chain Analysis
7.2 Human Cytomegalovirus Envelope Glycoprotein B Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Cytomegalovirus Envelope Glycoprotein B Production Mode & Process Analysis
7.4 Human Cytomegalovirus Envelope Glycoprotein B Sales and 麻豆原创ing
7.4.1 Human Cytomegalovirus Envelope Glycoprotein B Sales Channels
7.4.2 Human Cytomegalovirus Envelope Glycoprotein B Distributors
7.5 Human Cytomegalovirus Envelope Glycoprotein B Customer Analysis
8 Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Dynamics
8.1 Human Cytomegalovirus Envelope Glycoprotein B Industry Trends
8.2 Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Drivers
8.3 Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Challenges
8.4 Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Astellas Pharma Inc.
Trellis Bioscience, Inc.
Vakzine Projekt Management GmbH
VBI Vaccine Inc
Vical Incorporated

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.